ID: ALA4517424

Max Phase: Preclinical

Molecular Formula: C18H17IN2O3

Molecular Weight: 436.25

Molecule Type: Unknown

Representations

Canonical SMILES:  COc1cc(Nc2ccnc3ccc(I)cc23)cc(OC)c1OC

Standard InChI:  InChI=1S/C18H17IN2O3/c1-22-16-9-12(10-17(23-2)18(16)24-3)21-15-6-7-20-14-5-4-11(19)8-13(14)15/h4-10H,1-3H3,(H,20,21)

Standard InChI Key:  YULUHUJTIHWRMI-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 436.25

Molecular Weight (Monoisotopic): 436.0284

AlogP: 4.61

#Rotatable Bonds: 5

Polar Surface Area: 52.61

Molecular Species: NEUTRAL

HBA: 5

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 5

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 6.40

CX LogP: 4.03

CX LogD: 3.99

Aromatic Rings: 3

Heavy Atoms: 24

QED Weighted: 0.59

Np Likeness Score: -1.01

References

1. Asquith CRM, Berger BT, Wan J, Bennett JM, Capuzzi SJ, Crona DJ, Drewry DH, East MP, Elkins JM, Fedorov O, Godoi PH, Hunter DM, Knapp S, Müller S, Torrice CD, Wells CI, Earp HS, Willson TM, Zuercher WJ..  (2019)  SGC-GAK-1: A Chemical Probe for Cyclin G Associated Kinase (GAK).,  62  (5): [PMID:30768268] [10.1021/acs.jmedchem.8b01213]

2. Asquith CRM,Treiber DK,Zuercher WJ.  (2019)  Utilizing comprehensive and mini-kinome panels to optimize the selectivity of quinoline inhibitors for cyclin G associated kinase (GAK).,  29  (14.0): [PMID:31129055] [10.1016/j.bmcl.2019.05.025]

3. Saul S,Pu SY,Zuercher WJ,Einav S,Asquith CRM.  (2020)  Potent antiviral activity of novel multi-substituted 4-anilinoquin(az)olines.,  30  (16): [PMID:32631507] [10.1016/j.bmcl.2020.127284]

Source

Source(1):

• Scientific Literature